Menu Search
Equities

Soligenix Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
DOA0:MUN

Soligenix Inc

Actions
  • Price (EUR)3.54
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta2.0098
Data delayed at least 15 minutes, as of Oct 31 2024 07:07 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

  • Revenue in USD (TTM)0.00
  • Net income in USD-11.46m
  • Incorporated1987
  • Employees14.00
  • Location
    Soligenix Inc29 Emmons Drive, Suite B-10PRINCETON 08540United StatesUSA
  • Phone+1 (609) 538-8200
  • Fax+1 (609) 452-6467
  • Websitehttps://www.soligenix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.